Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2011-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research study is studying biomarkers in patients with rhabdomyosarcoma.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarker in Tumor Tissue Samples From Patients With Rhabdomyosarcoma
NCT01365962
Protein Expression in Samples From Young Patients With Rhabdomyosarcoma
NCT01426945
Studying Biomarkers in Samples From Patients With Rhabdomyosarcoma
NCT01433237
Biomarkers in Patients With Advanced Rhabdomyosarcoma
NCT01668095
Studying DNA in Tumor Tissue Samples From Patients With Localized or Metastatic Osteosarcoma
NCT01062438
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Determine genome-wide alterations in DNA methylation in ARMS and ERMS.
* Determine genome-wide DNA copy number alterations in ARMS and ERMS.
* Determine pathogenic genes and pathways by integrative genomic analysis.
OUTLINE: Genome-wide DNA-methylation analysis on ARMS, ERMS, and normal human skeletal myoblasts will be conducted using the HELP (HpaII tiny fragment Enrichment by Ligation-mediated PCR) assay. The methylation status of 1.3 million CpGs at promoters, gene bodies, and intergenic areas will be analyzed. Parallel gene expression analysis will be done and correlated with changes in methylation to uncover genes regulated by epigenetic alterations and altered by genomic losses or gains.
Genes that are altered by both genetic and epigenetic alterations in different sets of patients will be selected by the MIGHT (Multi-dimensional Integration of Genomic data from Human Tissues) algorithm to uncover new genes that are potentially involved in the pathogenesis of ARMS and ERMS. Gene ontology, pathway, and DNA motif analysis algorithms, and other computational approaches will be used to determine the biological consequences of the changes. Prioritized set of epigenetic and genetic alterations will be validated by bisulfite MassArray, FISH, and qRT-PCR in larger numbers of ARMS and ERMS samples.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DNA methylation analysis
fluorescence in situ hybridization
gene expression analysis
reverse transcriptase-polymerase chain reaction
laboratory biomarker analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 10 ARMS and 10 ERMS frozen samples will be collected from the COG bank via the Cooperative Human Tissue Network (CHTN)
* Human skeletal myoblasts (ZenBio, Research Triangle Park, NC) will serve as controls
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Caroline Y. Hu, MD
Role: PRINCIPAL_INVESTIGATOR
Tomorrows Children's Institute at Hackensack University Medical Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-ARST12B2
Identifier Type: OTHER
Identifier Source: secondary_id
ARST12B2
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2011-03634
Identifier Type: REGISTRY
Identifier Source: secondary_id
ARST12B2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.